Edition:
United States

argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

66.10EUR
11:38am EDT
Change (% chg)

€2.90 (+4.59%)
Prev Close
€63.20
Open
€63.90
Day's High
€66.60
Day's Low
€63.70
Volume
62,857
Avg. Vol
94,994
52-wk High
€94.80
52-wk Low
€18.90

Latest Key Developments (Source: Significant Developments)

Argenx Raises About $300.6 Millionin U.S. Public Offering
Friday, 21 Sep 2018 04:00pm EDT 

Sept 21 (Reuters) - ARGENX SE ::REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $300.6 MILLION.REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $300.6 MILLION.PRICE TO PUBLIC OF $86.50 PER ADS.GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 521,250 ADSS, REPRESENTING 15% OF ADSS SOLD.OPTION CAN BE EXERCISED DURING 30-DAY PERIOD COMMENCING SEPTEMBER 18, 2018..  Full Article

ArgenX Reports Positive Topline Results From Phase 2 Proof-Of-Concept Trial Of Efgartigimod In Primary Immune Thrombocytopenia
Monday, 17 Sep 2018 01:00am EDT 

Sept 17 (Reuters) - ARGENX SE ::REG-ARGENX REPORTS POSITIVE TOPLINE RESULTS FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD IN PRIMARY IMMUNE THROMBOCYTOPENIA.FAVORABLE SAFETY AND TOLERABILITY CONSISTENT WITH EFGARTIGIMOD CLINICAL TRIALS TO DATE.CLINICALLY MEANINGFUL PLATELET COUNT IMPROVEMENTS SHOWED CLEAR SEPARATION FROM PLACEBO AT INCREASING RESPONSE THRESHOLDS.PLAN TO ADVANCE ITP PROGRAM INTO PHASE 3 DEVELOPMENT.CIDP ANNOUNCED AS FOURTH INDICATION FOR EFGARTIGIMOD.ALSO EXPECTS TO INITIATE A PHASE 2 TRIAL IN ITP USING A SUBCUTANEOUS FORMULATION OF EFGARTIGIMOD.ANNOUNCED PLANS TO INITIATE A PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (IV) IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) H1 2019.  Full Article

Argenx Receives Feedback From Japan's PMDA On Phase 3 Clinical Trial
Wednesday, 29 Aug 2018 01:00am EDT 

Aug 29 (Reuters) - ARGENX SE ::REG-ARGENX RECEIVES FEEDBACK FROM JAPAN'S PMDA ON PHASE 3 CLINICAL TRIAL AND REGULATORY PATHWAY FOR EFGARTIGIMOD IN GENERALIZED MYASTHENIA GRAVIS.DATA FROM PLANNED GLOBAL PHASE 3 REGISTRATION TRIAL, IF POSITIVE, TO SERVE AS BASIS TO SUBMIT FOR MARKETING AUTHORIZATION IN JAPAN.PLANS TO INITIATE GLOBAL PHASE 3 REGISTRATION TRIAL OF EFGARTIGIMOD IN GMG BEFORE END OF 2018.EXPECTS DATA FROM PLANNED GLOBAL PHASE 3 REGISTRATION TRIAL, IF POSITIVE, WILL SERVE AS BASIS TO SUBMIT FOR MARKETING AUTHORIZATION IN JAPAN..GLOBAL PHASE 3 TRIAL EXPECTS TO ENROLL APPROXIMATELY 150 PATIENTS WITH GMG, INCLUDING PATIENTS FROM JAPAN AS WELL AS NORTH AMERICA AND EUROPE.DATA, IF POSITIVE, MAY SERVE AS BASIS FOR BIOLOGICS LICENSE APPLICATION IN U.S. BASED ON FEEDBACK FROM FDA.PATIENTS CAN ROLL OVER INTO AN OPEN-LABEL EXTENSION STUDY FOR A PERIOD OF ONE YEAR.  Full Article

Argenx Receives Milestone Payment From Strategic Collaboration With Shire
Tuesday, 17 Jul 2018 01:00am EDT 

July 17 (Reuters) - ARGENX SE ::REG-ARGENX RECEIVES MILESTONE PAYMENT FROM STRATEGIC COLLABORATION WITH SHIRE.HAS REACHED A PRECLINICAL MILESTONE IN ITS STRATEGIC COLLABORATION WITH SHIRE PLC.MILESTONE TRIGGERED BY SHIRE EXERCISING OPTION TO IN-LICENSE AN ANTIBODY DISCOVERED AND DEVELOPED USING CO'S SIMPLE ANTIBODY PLATFORM AND FC ENGINEERING TECHNOLOGIES.  Full Article

Argenx SE Says Euronext Has Selected Argenx SE For Inclusion In BEL 20 Index On Euronext Brussels
Tuesday, 5 Jun 2018 04:00pm EDT 

June 5 (Reuters) - argenx SE ::ARGENX SE SAYS EURONEXT HAS SELECTED ARGENX SE FOR INCLUSION IN BEL 20 INDEX ON EURONEXT BRUSSELS, EFFECTIVE JUNE 18, 2018.  Full Article

Argenx SE Files For Potential Mixed Shelf Offering
Friday, 1 Jun 2018 05:43pm EDT 

June 1 (Reuters) - argenx SE ::ARGENX SE FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Argenx To Present Complete Data From Phase 2 Proof-Of-Concept Trial Of Efgartigimod (Argx-113)
Tuesday, 24 Apr 2018 01:00am EDT 

April 24 (Reuters) - ARGENX NV ::REG-ARGENX TO PRESENT COMPLETE DATA FROM PHASE 2 PROOF-OF-CONCEPT TRIAL OF EFGARTIGIMOD (ARGX-113) IN GENERALIZED MYASTHENIA GRAVIS AT AMERICAN ACADEMY OF NEUROLOGY (AAN) ANNUAL MEETING.EIGHT-WEEK FOLLOW-UP DATA SHOW SEPARATION OF CLINICAL EFFICACY SCORES BETWEEN TREATMENT GROUP AND PLACEBO GROUP THROUGH DURATION OF STUDY.TOTAL AND PATHOGENIC IGG REDUCTION CORRELATES WITH DISEASE SCORE IMPROVEMENTS.  Full Article

Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma
Thursday, 12 Apr 2018 01:00am EDT 

April 12 (Reuters) - ARGENX ::TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX .AS PART OF AGREEMENT, ARGENX HAS GRANTED LEO PHARMA AN EXCLUSIVE OPTION TO OBTAIN A WORLDWIDE, EXCLUSIVE LICENSE TO ARGX-112 PROGRAM,.ARGX-112 PROGRAM AIMS TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS FOR INFLAMMATORY SKIN DISORDERS.MAY RECEIVE FURTHER REGULATORY AND CLINICAL MILESTONE PAYMENTS UP TO APPROX. EUR 100MM AS WELL AS ROYALTIES ON NET SALES OF ANY PRODUCT.  Full Article

Argenx Announces Closing Of U.S. Public Offering For Gross Proceeds Of About $266 Mln
Monday, 18 Dec 2017 04:01pm EST 

Dec 18 (Reuters) - Argenx Nv ::REG-ARGENX ANNOUNCES CLOSING OF U.S. PUBLIC OFFERING FOR GROSS PROCEEDS OF APPROXIMATELY $266 MILLION.‍EACH OF ADSS OFFERED REPRESENTS RIGHT TO RECEIVE ONE ORDINARY SHARE, NOMINAL VALUE OF EUR 0.10 PER SHARE​.‍CLOSING OF ITS PUBLIC OFFERING IN UNITED STATES OF 5,106,000 AMERICAN DEPOSITARY SHARES AT PRICE OF $52.00 PER ADS​.  Full Article

Argenx Raises About $231 Mln In Gross Proceeds In Upsized U.S. Offering
Wednesday, 13 Dec 2017 07:27pm EST 

Dec 14 (Reuters) - Argenx Nv ::ARGENX RAISES APPROXIMATELY $231 MILLION IN GROSS PROCEEDS IN AN UPSIZED U.S. PUBLIC OFFERING.‍ARGENX HAS GRANTED UNDERWRITERS AN OPTION TO PURCHASE UP TO AN ADDITIONAL 666,000 ADSS​.‍PRICING OF ITS PUBLIC OFFERING IN UNITED STATES WITH ANTICIPATED GROSS PROCEEDS ABOUT $231 MILLION FROM SALE OF 4,440,000 ADSS, AT $52/ADS​.  Full Article

Photo

AbbVie doubles down on cancer project with biotech group Argenx

BRUSSELS Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.